A 42-year-old woman with cirrhosis (Child-Pugh score 10) is prescribed warfarin for atrial fibrillation. Her baseline INR is 1.2. After a standard loading dose of 10 mg, her INR at 48 hours is 4.8 (therapeutic: 2–3). She has no signs of bleeding. Her serum albumin is 2.1 g/dL (normal: 3.5–5.5), and PT is prolonged at 18 seconds. Which pharmacokinetic mechanism BEST explains the exaggerated INR response to warfarin in this patient?

Explanation

## Warfarin Pharmacokinetics in Cirrhosis ### Dual Mechanism of Exaggerated Response The exaggerated INR response in cirrhosis results from **two converging pharmacokinetic and pharmacodynamic factors**: #### 1. Reduced Hepatic Metabolism of Warfarin **Key Point:** Warfarin is a highly lipophilic drug metabolized almost entirely by hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4, CYP1A2). In cirrhosis, hepatic synthetic function is severely impaired (Child-Pugh 10 indicates advanced disease), leading to: - Decreased metabolism of warfarin → prolonged half-life - Accumulation of active drug in plasma - Enhanced anticoagulant effect #### 2. Reduced Hepatic Synthesis of Clotting Factors **High-Yield:** Cirrhosis causes: - Impaired synthesis of vitamin K–dependent clotting factors (II, VII, IX, X) - Baseline prolongation of PT/INR (PT already 18 seconds) - Reduced hepatic reserve to compensate for warfarin's inhibition of factor synthesis **Clinical Pearl:** The combination of reduced warfarin clearance AND reduced clotting factor synthesis creates a **synergistic effect** — warfarin accumulates while the liver is already unable to synthesize adequate clotting factors. ### Why the INR is Disproportionately Elevated In a healthy patient, a standard 10 mg warfarin dose produces INR 2–3 over 48–72 hours. This patient's INR of 4.8 reflects: - Slower warfarin metabolism (reduced clearance) - Baseline hepatic dysfunction (low PT/INR at baseline) - Hypoalbuminemia (2.1 g/dL) → reduced warfarin protein binding → increased free (active) drug fraction ### Management Implications **Mnemonic: CIRRHOSIS warfarin dosing — **C**areful dose reduction, **I**NR monitoring frequent, **R**educed metabolism, **R**educed factors, **H**ypoalbuminemia increases free drug** Warfarin dosing in cirrhosis should be: - Reduced (typically 2–5 mg loading dose instead of 10 mg) - Monitored closely with INR checks every 2–3 days - Avoided if possible in decompensated cirrhosis (consider alternatives like LMWH or fresh frozen plasma for acute anticoagulation) ### Why Other Options Are Incorrect | Mechanism | Why Not Correct | |-----------|----------------| | Increased Vd (lipophilic accumulation) | Warfarin's Vd is small (~0.14 L/kg) and is not significantly altered in cirrhosis. Ascites increases total body water but not lipid compartment. Vd changes do not explain rapid INR elevation at 48 hours. | | Enhanced renal clearance | Warfarin is NOT renally eliminated; it is hepatically metabolized. Cirrhosis does not increase GFR — if anything, renal function is often impaired (hepatorenal syndrome risk). | | Increased protein binding | Hypoalbuminemia DECREASES (not increases) protein binding of warfarin, freeing more active drug. However, the primary driver of exaggerated response is reduced hepatic metabolism, not protein binding alone. |